- Investing Ideas
- /
- Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Taiwanese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Lotus Pharmaceutical
Market Cap: NT$83.8b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$338.00
7D
15.6%
1Y
29.8%
Bora Pharmaceuticals
Market Cap: NT$65.2b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$548.00
7D
6.0%
1Y
-15.9%